Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli‐D Study
Authors' conclusion
Once-daily iGlarLixi, injected before breakfast, was associated with improved HbA1c control and greater average 2-h PPG reductions compared with IDegAsp, regardless of injection time, in Chinese adults with T2D suboptimally controlled with OADs.
Study context
- Population
- Chinese adults with T2D suboptimally controlled with oral antidiabetic drugsIDegAsp n = 291
- Participants
- 582 adults
- Comparison
- Once-daily iGlarLixi vs IDegAsp
- iGlarLixin = 291
- IDegAsp breakfastn = 139reference
- IDegAsp lunchn = 54reference
- IDegAsp dinnern = 98reference
Methodological details24-week, multicentre, open-label, exploratory analysis by IDegAsp injection time
- 24-week
- Multicentre
- Open-label
- Exploratory analysis by IDegAsp injection time
Primary result
As reported in the abstract
Least squares mean difference
−0.24 %
−2.3 mmol/mol
iGlarLixi vs IDegAsp lunch · greater reduction with iGlarLixi
Least squares mean difference
−0.29 %
−3.2 mmol/mol
iGlarLixi vs IDegAsp dinner · greater reduction with iGlarLixi
Least squares mean difference
−0.12 %
−1.3 mmol/mol
iGlarLixi vs IDegAsp breakfast · slightly greater reduction with iGlarLixi
Further findings
Average 2-h PPG reduction
- Greater with iGlarLixi than IDegAsp, regardless of injection time
Body weight and total insulin dose
- Reduced body weight and lower total insulin doses with iGlarLixi vs IDegAsp in all injection-time subgroups
Safety
- Less hypoglycaemia risk with iGlarLixi vs IDegAsp in all injection-time subgroups
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →